Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Ovid Therapeutics Inc (OVID)

Ovid Therapeutics Inc (OVID)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 73,850
  • Shares Outstanding, K 71,010
  • Annual Sales, $ 390 K
  • Annual Income, $ -52,340 K
  • EBIT $ -69 M
  • EBITDA $ -68 M
  • 60-Month Beta 0.41
  • Price/Sales 186.58
  • Price/Cash Flow N/A
  • Price/Book 0.96

Options Overview Details

View History
  • Implied Volatility 203.93% ( -11.29%)
  • Historical Volatility 55.22%
  • IV Percentile 58%
  • IV Rank 22.88%
  • IV High 744.62% on 09/17/24
  • IV Low 43.53% on 12/20/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 10
  • Volume Avg (30-Day) 59
  • Put/Call OI Ratio 0.00
  • Today's Open Interest 1,039
  • Open Int (30-Day) 1,001

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 8 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.16
  • Number of Estimates 6
  • High Estimate -0.15
  • Low Estimate -0.18
  • Prior Year -0.22
  • Growth Rate Est. (year over year) +27.27%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.9877 +5.30%
on 11/19/24
1.4700 -29.25%
on 11/11/24
-0.1500 (-12.61%)
since 10/21/24
3-Month
0.9600 +8.33%
on 09/06/24
1.4700 -29.25%
on 11/11/24
-0.1500 (-12.61%)
since 08/21/24
52-Week
0.6800 +52.94%
on 06/26/24
4.1000 -74.63%
on 02/12/24
-2.2400 (-68.29%)
since 11/21/23

Most Recent Stories

More News
Ovid Therapeutics Reports Business Updates and Third Quarter 2024 Financial Results

OVID : 1.0400 (unch)
Ovid Therapeutics to Host Investor Event

OVID : 1.0400 (unch)
3 'Strong Buy'-Rated Stocks to Buy Now on the Dip

These outstanding growth stocks are worth buying on the dip.

AMZN : 196.74 (-3.03%)
$SPX : 5,926.23 (+0.15%)
GEHC : 82.26 (-3.11%)
GD : 280.97 (+0.33%)
OVID : 1.0400 (unch)
TAK : 13.27 (-0.19%)
Ovid Therapeutics Reports Second Quarter 2022 Financial Results and Corporate Highlights

Anticipates filing an Investigational New Drug application for OV329, a potent GABA-aminotransferase inhibitor, and initiating a Phase 1 trial in the...

OVID : 1.0400 (unch)
Ovid Therapeutics Presents Preclinical Data on OV329 at the Epilepsy Foundation Pipeline Conference

OV329 demonstrated robust anti-seizure activity in multiple preclinical seizure and epilepsy models, including treatment-resistant seizuresData demonstrate...

OVID : 1.0400 (unch)
Ovid Therapeutics Reports First Quarter 2022 Financial Results and Corporate Highlights

Ovid anticipates filing an investigational new drug application (IND) for OV329, a potent GABA aminotransferase inhibitor, and initiating Phase 1 trials in...

OVID : 1.0400 (unch)
Ovid Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference

NEW YORK, April 08, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...

OVID : 1.0400 (unch)
Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2021 Financial Results

Ovid executing on its strategy to build a leading epilepsy pipelineOV329 expected to enter the clinic in 2022Organization reshaped to reduce personnel by...

OVID : 1.0400 (unch)
Ovid Therapeutics to Participate at the Cowen 42nd Annual Health Care Conference

NEW YORK, March 04, 2022 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that...

OVID : 1.0400 (unch)
Healx and Ovid Therapeutics to Enter Strategic Partnership

– Ovid to License Gaboxadol to Healx – – Healx to Explore Gaboxadol in Combination Therapies for Fragile X, Other Indications – NEW YORK, N.Y. and...

OVID : 1.0400 (unch)

Business Summary

Ovid Therapeutics Inc. is a biopharmaceutical company. It engaged in developing therapies for patients with rare neurological disorders. The company's product pipeline consists of OV101, is currently in development for the treatment of symptoms of Angelman syndrome and Fragile X syndrome. It also involved...

See More

Key Turning Points

3rd Resistance Point 1.1003
2nd Resistance Point 1.0801
1st Resistance Point 1.0601
Last Price 1.0400
1st Support Level 1.0199
2nd Support Level 0.9997
3rd Support Level 0.9797

See More

52-Week High 4.1000
Fibonacci 61.8% 2.7936
Fibonacci 50% 2.3900
Fibonacci 38.2% 1.9864
Last Price 1.0400
52-Week Low 0.6800

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar